These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

131 related articles for article (PubMed ID: 9687218)

  • 1. Aminosalicylates in the treatment of children with inflammatory bowel disease. Summary of the workshop on aminosalicylate pharmacology.
    Ferry GD
    Inflamm Bowel Dis; 1998 May; 4(2):113-4; discussion 114-6. PubMed ID: 9687218
    [No Abstract]   [Full Text] [Related]  

  • 2. Aminosalicylates: old and new.
    Hanauer SB
    Mt Sinai J Med; 1990 Oct; 57(5):283-7. PubMed ID: 1982892
    [No Abstract]   [Full Text] [Related]  

  • 3. Effects of aminosalicylates on thiopurine S-methyltransferase activity: an ex vivo study in patients with inflammatory bowel disease.
    Xin H; Fischer C; Schwab M; Klotz U
    Aliment Pharmacol Ther; 2005 May; 21(9):1105-9. PubMed ID: 15854172
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Sulphasalazine and the aminosalicylates in the treatment of inflammatory bowel disease.
    Riley SA; Turnberg LA
    Q J Med; 1990 Jun; 75(278):551-62. PubMed ID: 1977185
    [No Abstract]   [Full Text] [Related]  

  • 5. [New derivates of salazopyrine in the treatment of chronic inflammatory bowel disease].
    Broide E; Scapa E; Abramowich D; Eshchar Y
    Harefuah; 1993 Feb; 124(4):223-5. PubMed ID: 8098698
    [No Abstract]   [Full Text] [Related]  

  • 6. Update on the aminosalicylates: a promise fulfilled.
    Peppercorn MA
    Gastroenterology; 1988 Dec; 95(6):1677-80. PubMed ID: 2903113
    [No Abstract]   [Full Text] [Related]  

  • 7. Risk-benefit assessment of drugs used in the treatment of inflammatory bowel disease.
    Hanauer SB; Stathopoulos G
    Drug Saf; 1991; 6(3):192-219. PubMed ID: 1676590
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Aminosalicylates in the treatment of idiopathic inflammatory bowel disease].
    Lukás K
    Vnitr Lek; 1996 Feb; 42(2):117-9. PubMed ID: 8686186
    [No Abstract]   [Full Text] [Related]  

  • 9. New light on the anti-colitic actions of therapeutic aminosalicylates: the role of heme oxygenase.
    Whittle BJ; Varga C
    Pharmacol Rep; 2010; 62(3):548-56. PubMed ID: 20631420
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [5-ASA versus sulfasalazine].
    Varela E
    Acta Gastroenterol Latinoam; 1994; 25(5):317-9. PubMed ID: 7785405
    [No Abstract]   [Full Text] [Related]  

  • 11. Dipentum (olsalazine sodium).
    Swartz ML
    Gastroenterol Nurs; 1991 Dec; 14(3):144-7. PubMed ID: 1760451
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Aminosalicylates and colorectal cancer in IBD: a not-so bitter pill to swallow.
    Ryan BM; Russel MG; Langholz E; Stockbrugger RW
    Am J Gastroenterol; 2003 Aug; 98(8):1682-7. PubMed ID: 12907319
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Aminosalicylates for the treatment of inflammatory bowel disease.
    Leichtner AM
    J Pediatr Gastroenterol Nutr; 1995 Oct; 21(3):245-52. PubMed ID: 8523207
    [No Abstract]   [Full Text] [Related]  

  • 14. Drug insight: aminosalicylates for the treatment of IBD.
    Nielsen OH; Munck LK
    Nat Clin Pract Gastroenterol Hepatol; 2007 Mar; 4(3):160-70. PubMed ID: 17339853
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Tolerability of aminosalicylates in inflammatory bowel disease.
    Ishaq S; Green JR
    BioDrugs; 2001; 15(5):339-49. PubMed ID: 11437696
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Aminosalicylates in the treatment of inflammatory bowel disease.
    Sutherland LR
    Inflamm Bowel Dis; 1998 May; 4(2):113. PubMed ID: 9687217
    [No Abstract]   [Full Text] [Related]  

  • 17. Controversies with aminosalicylates in inflammatory bowel disease.
    Lim WC; Hanauer SB
    Rev Gastroenterol Disord; 2004; 4(3):104-17. PubMed ID: 15359211
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Inflammatory bowel diseases, 5-aminosalicylic acid and sulfasalazine treatment and risk of acute pancreatitis: a population-based case-control study.
    Munk EM; Pedersen L; Floyd A; Nørgård B; Rasmussen HH; Sørensen HT
    Am J Gastroenterol; 2004 May; 99(5):884-8. PubMed ID: 15128355
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Combination of purine analogues and aminosalicylates in patients with inflammatory bowel disease: why and how?].
    Jomni T; Dray X; Marteau P
    Gastroenterol Clin Biol; 2007; 31(8-9 Pt 1):758-60. PubMed ID: 17925782
    [No Abstract]   [Full Text] [Related]  

  • 20. [Salicylic derivatives in the clinical treatment of inflammatory bowel disease: new perspectives].
    Damião AO; Sipahi AM
    Rev Hosp Clin Fac Med Sao Paulo; 1989; 44(5):271-8. PubMed ID: 2576896
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.